Effect of adjuvant androgen deprivation on thyroid function tests in prostate cancer patients

Salminen, Eeva; Koskinen, Aki; Bäckman, Helena; Nurmi, Martti

doi:10.1097/00001813-200404000-00007

Cited by 7 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A preliminary report of ten men with advanced prostate cancer found declines in free triiodothyronine (T3) levels but not free thyroxine (T4) levels over a 12-month period [113]. Two groups more recently explored this issue using case-control designs [114,115]. Salminen et al prospectively measured levels of thyroid stimulating hormone (TSH), free thyroxine, and thyroid binding globulin (TBG) in 35 men on ADT and compared it to 36 men undergoing radiotherapy alone [114].…”

Section: Thyroid Dysfunctionmentioning

confidence: 99%

“…Two groups more recently explored this issue using case-control designs [114,115]. Salminen et al prospectively measured levels of thyroid stimulating hormone (TSH), free thyroxine, and thyroid binding globulin (TBG) in 35 men on ADT and compared it to 36 men undergoing radiotherapy alone [114]. Over 12 months of follow-up, TSH and TBG levels remained unchanged but free thyroxine levels declined slightly (from 12.4 to 11.4 pmol/L, p = 0.001).…”

Section: Thyroid Dysfunctionmentioning

confidence: 99%

“…A small but statistically significant increase in TSH levels (1.81 mU/L in ADT cases, 1.58 mU/L in controls, p = 0.007) and decrease in free thyroxine levels (1.18 ng/dL versus 1.24 ng/dL, respectively, p = 0.018) were noted. Although Salminen et al hypothesized that LHRH agonists may have some previously uncharacterized activity upon the TSH receptor [114], Morote et al correctly pointed out that the clinical significance of a small increase in TSH levels is dubious [115]. The limited available data do not suggest routine monitoring of thyroid function tests is warranted in men undergoing ADT, although further studies are needed.…”

Section: Thyroid Dysfunctionmentioning

confidence: 99%

See 2 more Smart Citations

Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review

Alibhai

Gogov

Allibhai

2006

Critical Reviews in Oncology/Hematology

158

111

View full text Add to dashboard Cite

Section: Thyroid Dysfunctionmentioning

confidence: 99%

Section: Thyroid Dysfunctionmentioning

confidence: 99%

Section: Thyroid Dysfunctionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review

Alibhai

Gogov

Allibhai

2006

Critical Reviews in Oncology/Hematology

158

111

View full text Add to dashboard Cite

“…In cases of benign prostatic hyperplasia, no significant changes in the level of TSH were noted after surgery. [14] In another prospective study by Salminen et al (2004), levels of serum thyroid stimulating hormones (TSH), free thyroxine (fT4) and thyroid binding globulin concentrations were measured in prostate cancer patients treated with either radiotherapy and androgen deprivation for 12 months (AD) or radical radiotherapy alone. The study concluded that prolonged use of AD hampers the interpretation of thyroid test results by causing a significant decline in fT4 at 6 and 12 months.…”

Section: Slmentioning

confidence: 99%

“…The study concluded that prolonged use of AD hampers the interpretation of thyroid test results by causing a significant decline in fT4 at 6 and 12 months. [15] A study by Frokovic et al (1994) reported development of TSH-secreting small cell prostate cancer (SCPC) from highgrade adenocarcinoma (Gleason score 8) with an elevated number of chromogranin A positive cells located in benign structures adjacent to the cancer. Conversion to SCPC was followed up during 4 years.…”

Section: Slmentioning

confidence: 99%

A Study on Relation of Thyroid Stimulating Hormone Level With Skeletal Metastasis in Carcinoma Prostate Patients

Sharma¹,

Sharma²,

Sethi³

et al. 2017

jemds

View full text Add to dashboard Cite

BACKGROUND Prostate, a genital organ, secretes fluid, seminal plasma, the possible function of which is to provide nutrition to the sperms and serve as their vehicle during ejaculation. Prostate is of great clinical importance because of its affinity for inflammatory, congestive, hyperplastic and neoplastic diseases. Majority of instances of prostatic pathology are manifested by derangement of urination owing to the intimate anatomical relationship between urinary bladder and prostate. We studied serum TSH Levels in patients of BPH and CA prostate and its relation with skeletal metastasis.This descriptive study was aimed to study any correlation between Serum TSH level and bone metastasis in patients with Prostate carcinoma. MATERIALS AND METHODSThis descriptive study was conducted at Rabindranath Tagore Medical College and Maharana Bhupal Government Hospital, Udaipur, Rajasthan in the Department of Surgery. A non-statistical sample size of 50 patients suffering from benign prostatic hyperplasia or prostate cancer was taken as per convenience. The patients were divided into 2 groups, 25 patients of BPH based on serum PSA estimation (control) and 25 patients of prostate cancer based on serum PSA estimation (test). Preoperative estimation of serum TSH and serum PSA was done in all the patients. All the patients were operated (TURP or palliative TURP). The results of serum TSH, serum PSA, and Gleason score were then analysed and a relation between increasing levels of serum TSH, serum PSA, and Gleason grade was sought based on exploratory data analysis (EDA). RESULTSSerum PSA level in most of the BPH patients was found to be within normal limit and serum TSH level in all of the BPH patients was found to be within normal limits. Only in 8% cases of Prostate carcinoma patients had very high PSA level (>100 ng/mL) as well as increased serum TSH level and it was associated with Gleason score 8 (high-grade tumour) and skeletal metastases. Further statistical/epidemiological studies are required for confirmation of these findings. CONCLUSIONOnly in 8% cases of Prostate carcinoma patients had a very high PSA level (>100 ng/mL) as well as increased serum TSH level, and it was associated with Gleason score 8 (high-grade tumour) and skeletal metastases. Further statistical/epidemiological studies are required for confirmation of these findings.

show abstract

Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases

Liu

Chen

et al. 2022

The Prostate

View full text Add to dashboard Cite

Background Androgen deprivation therapy (ADT) is the major treatment for metastatic prostate cancer (PCa), but few studies have investigated the effects of ADT on thyroid diseases. Methods This population‐based, nationwide cohort study utilized the Taiwan National Health Insurance Research Database (NHIRD) with 17,192 PCa patients between 1997 and 2013. We used the Cox proportional hazards models and propensity score‐matched analysis to analyze the association between ADT and the development of thyroid diseases. Results A total of 17,192 newly diagnosed men with PCa were selected from the NHIRD. There were 6200 ADT users and 6200 non‐ADT users after 1:1 propensity score matching. There was a significantly decreased risk of thyroid diseases among ADT users compared with non‐ADT users (adjusted hazard ratio (aHR): 0.79, 95% confidence interval (CI): 0.65–0.95, p < 0.001). Further analysis showed a significantly decreased risk of thyroid diseases with increasing ADT duration (p < 0.001). Conclusions The result showed that ADT use in men with PCa was associated with a decreased risk of thyroid disease development.

show abstract

Effect of adjuvant androgen deprivation on thyroid function tests in prostate cancer patients

Cited by 7 publications

References 18 publications

Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review

Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review

A Study on Relation of Thyroid Stimulating Hormone Level With Skeletal Metastasis in Carcinoma Prostate Patients

Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases

Contact Info

Product

Resources

About